profit from every $100 of sales.
$0$100
Teva Pharmaceutical Industries
$44.50+1.95% today
+74.2% in 1 year
1-year low $24.211-year high $44.50
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $36.83 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Teva Pharmaceutical Industries sold, what it kept, and what it did with the cash.
Sales went from $14.9 billion in 2022 to $17.3 billion in 2025, with $1.41 billion of profit last year.
SalesProfit
Teva Pharmaceutical Industries vs. similar companies
Teva Pharmaceutical Industries grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Teva Pharmaceutical Industries | 36.8× · Expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Sun Pharmaceutical Industries | 39.3× · Expensive |
AI analysis
An AI analyst reads Teva Pharmaceutical Industries's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 16,659 | 15,878 | 14,925 | 15,845 | 16,544 | 17,257 | |
| 7,726 | 7,594 | 6,973 | 7,645 | 8,064 | 8,938 | |
| – | – | 2,690 | 3,194 | 3,364 | 3,952 | |
| -1,948 | 2,879 | -925 | 1,558 | 777 | 3,141 | |
| -3,990 | 417 | -2,446 | -559 | -1,639 | 1,410 | |
| -3.64 | 0.38 | -2.12 | -0.50 | -1.45 | 1.21 | |
| 46.4% | 47.8% | 46.7% | 48.2% | 48.7% | 51.8% | |
| – | – | 18.0% | 20.2% | 20.3% | 22.9% | |
| -24.0% | 2.6% | -16.4% | -3.5% | -9.9% | 8.2% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 50,640 | 47,666 | 44,011 | 43,479 | 39,326 | 40,748 |
| Cash | 2,177 | 2,165 | 2,801 | 3,226 | 3,300 | 3,556 |
| Total debt | – | – | 21,561 | 20,153 | 18,079 | 17,094 |
| Total liabilities | 39,579 | 36,422 | 35,413 | 35,353 | 33,606 | 32,834 |
| 10,026 | 10,278 | 7,804 | 7,506 | 5,373 | 7,910 | |
| 1,095 | 1,107 | 1,110 | 1,119 | 1,131 | 1,163 | |
| -27.6% | 11.9% | -6.0% | 1.2% | -0.9% | 6.8% | |
| -39.8% | 4.1% | -31.3% | -7.4% | -30.5% | 17.8% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,216 | 798 | 1,590 | 1,368 | 1,247 | 1,649 | |
| 578 | 562 | 548 | 526 | 498 | 501 | |
| 638 | 236 | 1,042 | 842 | 749 | 1,148 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 129 | 119 | 124 | 121 | 123 | 157 |
Valuation
- 36.8×
- 18.8×
- –
- 6.2×
- 3.0×
- 45.2×
- 20.8×
- 2.2%
- 2.7%
- 0.0%
Profitability
- 51.8%
- 22.9%
- 8.2%
- 19.0%
- 6.9%
- 0.3%
- 20.8%
- 3.9%
- 12.6%
- 5.7%
Growth
- +0.7%
- –
- +53.3%
- –
- +1.6%
Financial health
- 4.3×
- 2.16
- 42.2%
- 2.3×
- 1.04
- 0.78
- 0.43
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 43%of 946
Top 18%of 872
Bottom 36%of 564
Bottom 17%of 867
Top 41%of 986
What analysts expect
- Average price target
- $39.00
- Range
- $35.00 – $42.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | 0.53 | 0.50 | +6.0% |
| Jan 28, 2026 | 0.96 | 0.65 | +47.7% |
| Nov 5, 2025 | 0.78 | 0.68 | +14.7% |
| Jul 30, 2025 | 0.66 | 0.63 | +4.8% |
| May 7, 2025 | 0.52 | 0.47 | +10.6% |
| Jan 29, 2025 | 0.71 | 0.69 | +2.9% |
| Nov 6, 2024 | 0.69 | 0.65 | +6.2% |
| Jul 31, 2024 | 0.61 | 0.57 | +7.0% |
News
Teva names Serge Rogasik as CEO of API, CDMO businessSeeking Alpha · Sep 30, 2026Aurinia settles Lupkynis patent litigation with TevaSeeking Alpha · Aug 19, 2026The newest story we have is from Sep 30, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
12No pass
Philip Fisher
37No pass
Peter Lynch
24No pass
Joel Greenblatt
5No pass
Charlie Munger
27No pass
Terry Smith
25No pass
Questions about Teva Pharmaceutical Industries
Is Teva Pharmaceutical Industries a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Teva Pharmaceutical Industries AI analysis
What does Teva Pharmaceutical Industries do?
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Tel Aviv-Yafo, Israel, with 31,173 employees.
Does Teva Pharmaceutical Industries pay a dividend?
No. Teva Pharmaceutical Industries does not pay a dividend at the moment.
Is Teva Pharmaceutical Industries stock halal?
No. Teva Pharmaceutical Industries does not pass our halal screen: its debt is 34% of its market value, at or above the 33% limit. How we check
How has Teva Pharmaceutical Industries stock done over the past year?
Up 74.2% over the past twelve months, to $44.50. It traded between $24.21 and $44.50, close to its high.
Who are Teva Pharmaceutical Industries's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Sun Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Teva Pharmaceutical Industries's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.